 |
 |
 |
| Vanita R. Aroda, MD | Mark W. Feinberg, MD | Marc S. Sabatine, MD, MPH |
Brigham and Women’s Hospital was selected by the American Heart Association (AHA) to lead one of four new centers charged with better understanding the pathobiology and treatments of cardiometabolic health and type 2 diabetes.
The Brigham-based center, co-directed by Mark W. Feinberg, MD, and Marc S. Sabatine, MD, MPH, will receive a four-year Strategically Focused Research Network (SFRN) grant from the AHA, totaling $3.5 million, to support their network entitled “Strategies to Understand Pathobiology, Predictors, and Pharmacotherapy to Reduce Adverse Cardiovascular Outcomes in T2DM (SUPER-CVDM).” Feinberg is a cardiologist and director of the Program in Cardiovascular RNA Biology in the Division of Cardiovascular Medicine. Sabatine, also a cardiologist, is chair of the Thrombolysis in Myocardial Infarction (TIMI) Study Group at the Brigham.
The research center will include three collaborative studies at Brigham and Women’s Hospital and Boston University School of Medicine (BUSM), led by Feinberg, Sabatine and Naomi M. Hamburg, MD, section chief of Vascular Biology at BUSM, for understanding mechanisms that cause disease, defining predictors, evaluating therapies and ultimately identifying the populations at highest risk and patients who gain the greatest benefit from therapy. Some of the team’s research will focus on African Americans, a population that is at higher risk for cardiovascular complications.
The research team is joined by Vanita R. Aroda, MD, of the Brigham’s Division of Endocrinology, Diabetes and Hypertension, and Jessica L. Fetterman, PhD, of BUSM’s Department of Medicine, who will serve as center training co-directors, and by Wendy B. White, PhD, of Tougaloo College, to expand scientific mentorship of minority students.
In addition to the Brigham, the AHA’s other three SFRN-funded centers will be led by Johns Hopkins University, New York University and the University of Iowa. Collectively supported by over $14 million in grant funding, these four teams will pursue innovative breakthroughs to better understand issues surrounding heart disease, strokes and type 2 diabetes.
The American Heart Association is a national nonprofit dedicated to being a leading force for a world of longer, healthier lives.
Learn more about the four SFRNs and their projects.
